What is the appropriate medication management for a patient with shoulder impingement syndrome and chronic kidney disease stage 1?

Medication Management for Shoulder Impingement Syndrome in CKD Stage 1

For shoulder impingement syndrome in a patient with CKD stage 1 (eGFR ≥90 mL/min/1.73 m²), use acetaminophen as first-line oral analgesic, followed by short-course NSAIDs (≤7-10 days) with careful monitoring if acetaminophen fails, and consider subacromial corticosteroid or NSAID injections for persistent symptoms.

Oral Analgesic Strategy

First-Line: Acetaminophen

• Start with acetaminophen (up to 3-4 grams daily in divided doses) as the safest oral analgesic option 1
• No dose adjustment needed in CKD stage 1
• Minimal nephrotoxicity risk compared to NSAIDs

Second-Line: Short-Course NSAIDs

If acetaminophen provides inadequate pain relief:

• NSAIDs can be used cautiously in CKD stage 1 for short durations (≤7-10 days) with careful monitoring 2, 1
• CKD stage 1 represents the lowest risk category for NSAID-related nephrotoxicity since baseline kidney function is preserved
• Monitor for:
  • Acute kidney injury (check creatinine after 7-10 days of use)
  • Blood pressure elevation
  • Fluid retention/edema
  • Electrolyte derangements (hyperkalemia)

Key caveat: The risk of NSAID nephrotoxicity increases with:

• Concurrent use of ACE inhibitors, ARBs, or diuretics
• Volume depletion
• Heart failure
• Diabetes
• Age >65 years

If any of these risk factors are present, limit NSAID duration to <7 days or avoid entirely 2.

Injection Therapy

Subacromial Injections - Equally Effective Options

Both corticosteroid and NSAID injections are equally effective for short-term pain relief and functional improvement 3:

• Subacromial corticosteroid injection (SCI): Traditional approach, well-established efficacy
• Subacromial NSAID injection (SNI): Equally effective as corticosteroids with lower cost (ketorolac costs $0.47 vs. higher corticosteroid costs) and no significant difference in side effects 3

SNIs represent a cost-effective alternative to corticosteroids with equivalent outcomes at 2-12 weeks follow-up 3. This is particularly relevant for patients concerned about corticosteroid-related side effects (hyperglycemia, tendon weakening with repeated injections).

Adjunctive Therapies to Enhance Outcomes

Do not rely on medications alone - exercise-based therapy is critical:

• Exercise therapy combined with injections shows superior outcomes compared to injections alone 4
• Physical therapy focusing on rotator cuff strengthening and scapular stabilization should be initiated concurrently
• Combined treatments (exercise + injection) demonstrate better pain scores and Constant-Murley scores than single interventions 4

Avoid: Localized NSAID injections used alone without exercise therapy show worse outcomes 4.

Medications to Avoid

• Opioids should be minimized or avoided - reserve only for patients who fail all other therapies given increased adverse events in CKD populations 1
• Low-level laser therapy and isolated NSAID injections (without exercise) are not recommended 4
• Chronic NSAID use (>2-4 weeks) should be avoided due to cumulative nephrotoxicity risk even in CKD stage 1 2

Monitoring Protocol for NSAID Use

If NSAIDs are prescribed:

1. Baseline: Check serum creatinine, potassium, blood pressure
2. After 7-10 days: Recheck creatinine and potassium
3. Discontinue immediately if creatinine rises >0.3 mg/dL or potassium >5.0 mmol/L
4. Limit total duration to 7-10 days maximum for oral NSAIDs 2, 1

Clinical Algorithm Summary

1. Start acetaminophen (3-4 g/day divided) + physical therapy
2. If inadequate response after 1-2 weeks: Add short-course oral NSAID (≤7-10 days) with monitoring OR proceed directly to injection
3. If persistent symptoms: Subacromial injection (NSAID or corticosteroid - choose NSAID for cost-effectiveness) + continue physical therapy
4. If failure after 6-12 weeks of conservative management: Consider surgical referral for arthroscopic subacromial decompression 4, 5

The key principle: CKD stage 1 allows more flexibility with NSAIDs than advanced CKD, but duration and monitoring remain critical to prevent progression of kidney disease.